A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Thymoma
- Focus Therapeutic Use
- 08 Jul 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 27 Nov 2018 Planned End Date changed from 1 Nov 2018 to 31 Dec 2018.
- 05 Jun 2018 Results (n=14) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.